

EUROPEAN COMMISSION

HEALTH & CONSUMERS DIRECTORATE-GENERAL

Public Health and Risk Assessment **Risk assessment**

Scientific Committee on Consumer Safety

3rd meeting of the WG 'Cosmetic Ingredients' – 30 June 2009

Minutes

1. WELCOME AND APOLOGIES

The Chair of the working group (WG) welcomed the participants and communicated the apologies received.

2. ADOPTION OF THE AGENDA

The draft agenda was adopted (annex 1).

3. DECLARATION OF INTEREST ON MATTERS OF THE AGENDA

No member declared any interest that could prevent him/her from participating in the discussion of the items on the agenda.

4. DRAFT OPINIONS

- 4.1. Cyclomethicone (D4)
- 4.2. Clarification on Choline salts and esters
- 4.3. CMR substances, borate
- 4.4. S74, Polysilicone-15 (Inhalation only)

5. PROGRESS REPORTS

- 5.1. P81, Zinc pyrithione
- 5.2. Erythrosine
- 5.3. Melatonin

6. OBJECTION TO PREVIOUS OPINIONS

6.1. Objection to Alkyl (C16, C18, C22) triethylammoniumchloride

- 6.2. Benzophenone-3
- 6.3. Camphor benzalkonium methosulfate

7. ANY OTHER BUSINESS

No specific items were raised.

The next meeting will take place on 2 September 2009.

Annex 1: draft agenda

Annex 1

Scientific Committee on Consumer Safety (SCCS) WG on Cosmetic Ingredients

30 June 2009

	DRAFT AGENDA
1.	WELCOME AND APOLOGIES
2.	ADOPTION OF THE AGENDA
3.	DECLARATION OF INTEREST ON MATTERS ON THE AGENDA
4.	DRAFT OPINIONS ON:
4.1. 4.2. 4.3. 4.4.	Chloro methyl isothiazolinone / methyl isothiazolinone (CMI/MI) Cyclomethicone (D4) Clarification on Choline salts and esters CMR substances, borate
5.	RESPONSES TO PREVIOUS OPINIONS
5.1. 5.2. 5.3 5.4	Objection to Alkyl (C16, C18, C22) triethylammoniumchloride Response to the public consultation on benzophenone-3 Response to the public consultation on Camphor benzalkonium methosulfate TTO
6.	PROGRESS REPORTS
6.1. 6.2.	P81, Zinc pyrithione S74, Polysilicone-15

- Erythrosine 6.3.
- 6.4. Melatonin

7. **NEW REQUESTS**

- 7.1 Vitamin K1
- **ANY OTHER BUSINESS** 8.